In:
Journal of International Medical Research, SAGE Publications, Vol. 18, No. 6 ( 1990-11), p. 483-488
Abstract:
An open clinical trial was performed to assess the efficacy and safety of 400 μg tulobuterol aerosol given four times daily in childhood bronchial asthma. A total of 54 children were enrolled with bronchial asthma shown to be reversible by an increase of forced expiratory volume in 1 s (FEV 1 ) of more than 15% following 200 (μg of salbutamol. Tulobuterol was administered for 3 weeks and regular use of salbutamol was continued for 12 patients during the 7-day lead-in period and six patients took theophylline throughout the study; other drugs were discontinued. The mean FEV 1 , mean adjusted FEV 1 , mean peak expiratory flow rate (PEFR) and mean forced vital capacity (FVC) were significantly increased ( P 〈 0.001) following treatment. Mean FEV 1 increases ranged from 9.2% to 14.0%, with 24.5 – 43.4% of patients showing clinically significant increases of at least 15%. Globally, there was improvement in 46 patients (85%). Headache and nervous system complaints were the most common side-effects. Although this was an uncontrolled study, the indications are that tulobuterol aerosol is effective and safe for use in children with asthma.
Type of Medium:
Online Resource
ISSN:
0300-0605
,
1473-2300
DOI:
10.1177/030006059001800606
Language:
English
Publisher:
SAGE Publications
Publication Date:
1990
detail.hit.zdb_id:
2082422-1
Permalink